IA
LXRX icon

IFP Advisors’s Lexicon Pharmaceuticals LXRX Stock Holding History

IFP Advisors’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1
Closed -$1 – 4980
2025
Q3 		$1 Hold
1
– – ﹤0.01% 4827
2025
Q2 		$1 Buy
+1
New +$1 ﹤0.01% 4906
2024
Q2 		– Sell
-150
Closed -$360 – 3291
2024
Q1 		$360 Buy
+150
New +$322 ﹤0.01% 3004
2023
Q1 		– Sell
-2,000
Closed -$25K – 4002
2022
Q4 		$25K Buy
+2,000
New +$4.26K ﹤0.01% 2717
2019
Q1 		$0 Buy
+1
New +$6 ﹤0.01% 2962
2018
Q2 		– Sell
-300
Closed -$3K – 3980
2018
Q1 		$3K Hold
300
– – ﹤0.01% 3387
2017
Q4 		$3K Sell
300
-1,822
-86% -$18.9K ﹤0.01% 3437
2017
Q3 		$26K Sell
2,122
-55
-3% -$812 ﹤0.01% 2433
2017
Q2 		$36K Sell
2,177
-470
-18% -$7.28K ﹤0.01% 2183
2017
Q1 		$38K Buy
2,647
+2,625
+11,932% +$38.9K ﹤0.01% 2085
2016
Q4 		$0 Sell
22
-14,252
-100% -$229K ﹤0.01% 4066
2016
Q3 		$258K Buy
+14,274
New +$230K 0.01% 879
2016
Q2 		– Sell
-1
Closed – – 3966
2016
Q1 		$0 Buy
+1
New +$10 ﹤0.01% 2957

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CIBC Private Wealth Group
CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return

IFP Advisors's LXRX Position: Q4 2025 in Review

IFP Advisors sold out of Lexicon Pharmaceuticals (LXRX) in Q4 2025, closing a stake of 1 share — an estimated $1 sold.

IFP Advisors first reported a position in LXRX in Q1 2016 and held it in 13 quarters. The position peaked at $258K in Q3 2016. 125 funds tracked by Wall St. Rank hold LXRX as of Q4 2025.

  • IFP Advisors reported no remaining Lexicon Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • IFP Advisors sold 1 Lexicon Pharmaceuticals share in Q4 2025, an estimated $1.
  • IFP Advisors first reported a position in Lexicon Pharmaceuticals in Q1 2016 and held it in 13 quarters.
  • IFP Advisors's Lexicon Pharmaceuticals position peaked at $258K in Q3 2016.
  • 125 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q4 2025.

Based on IFP Advisors's 13F filing for Q4 2025, filed 6 Feb 2026.